Pozen Says FDA Blocked Drug Products Over Quality Lapses
North Carolina drugmaker Pozen Inc. on Monday said the U.S. Food and Drug Administration has refused to approve two products targeting cardiovascular and gastrointestinal disorders because of an active ingredient supplier's...To view the full article, register now.
Already a subscriber? Click here to view full article